Patented technology "innovative" and with "industrial applicability"

Tel-Array filed an international patent application on the Spot Profiler biosensor and cartridge system in September 2017, which was reviewed by the Canadian Patent Office and subsequently published in April 2018.

The International Search Authority (ISA) concludes the technology to be “innovative” and with “industrial applicability”.

National patent applications to be filed in 2019 in select countries of interest.

Categories: Publication

Published on by Winnie So.

Meeting with Dr. Saul Isserow

Tel-Array co-founders and management had an insightful meeting with Scientific Advisory Board member, Dr. Saul Isserow to discuss the future of the company's technology and products.

Dr. Isserow is the Director of both Cardiovascular Health at Vancouver General Hospital (VGH) and Cardiology Services at University of British Columbia Hospital (UBC Hospital). He is a leading figure in the cardiology medical field and well-connected with other medical and laboratory specialists.

Tel-Array appreciates the time and support Dr. Isserow provides to the company, especially with respect to Tel-Array's cardiovascular disease test panel. Tel-Array looks forward to continuing the relationship with Dr. Isserow and reaching other members of the medical community.

Dr. Saul Isserow (middle) and Tel-Array co-founders Dr. Hong Zhang (left) and Dr. William Campbell (right)

Dr. Saul Isserow (middle) and Tel-Array co-founders Dr. Hong Zhang (left) and Dr. William Campbell (right)

Categories: Meeting

Published on by Winnie So.

Funding awarded for the second time from the Government of Canada

Tel-Array Diagnostics Inc. was awarded up to $350,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) for the pre-commercialization of its smartphone-integrated biomarker sensor system. This is the second round of funding Tel-Array has received from NRC-IRAP; the first being in 2015 in the amount of $483,500 for the development of this biosensor technology platform proof of concept. Over the past two years, Tel-Array has made significant progress in its technology development and is now ready to embark on pre-commercialization efforts to bring the biomarker sensor system to market in 2018.

Tel-Array thanks NRC-IRAP for its continued support.

Categories: Funding

Published on by Winnie So.

Meeting with Dr. Max Cynader

Tel-Array co-founders and management had a fruitful meeting with Scientific Advisory Board member, Dr. Max Cynader to discuss the future of the company's technology and products.

Dr. Cynader is a prominent member of the scientific community and is the Founding Director of the Brain Research Centre, and the Djavad Mowafaghian Centre for Brain Health at Vancouver Coastal Health and University of British Columbia (UBC). In addition, he holds the Canada Research Chair in Brain Development and is Professor of Ophthalmology at UBC. Dr. Cynader is also a Member of the Order of Canada (CM), Member of the Order of British Columbia (OBC), Principal Investigator in Canada's Network of Excellence in Stroke, as well as recipient of many other awards and appointments. Moreover, Dr. Cynader has also been active in the industry, founding multiple companies including NeuroVir, Wavemakers Research, Primary Peptides, and Synaptitude.

Tel-Array appreciates the time and support Dr. Cynader provides to the company, and the network and industry experience Dr. Cynader brings to Tel-Array.

Dr. Max Cynader (2nd from the left) and Tel-Array co-founders and management

Dr. Max Cynader (2nd from the left) and Tel-Array co-founders and management

Categories: Meeting

Published on by Winnie So.